design: Essential gene screening identifies the Bromodomain-Containing Protein BRPF1 as a new therapeutic target for endocrine therapy-resistant breast cancer
library_construction_protocol: BRPF1 knock-down was performed plating approximately 3000 cells in each well of a 96-well plate in standard growth medium. After overnight incubation, transient transfection was assessed by using Lipofectamine RNAiMax (13778-150, Invitrogen) diluted in Optimem medium, according to the manufacturer's instructions. 0.5 pM/well of two validated BRPF1 siRNAs (s17208, s17210) or scramble Silencer Select Negative Control (SiSel_NC1) (Ambion, Thermo Fisher Scientific) were added in quadrupled/sixfold each one and incubated for 72h at 37 °C/5% CO2. Total RNA was extracted from all cell lines aafter siRNA-transfection using TRIzol reagent (Life Technologies, Carlsbad, CA), according to the manufacturer's instructions  indexed libraries were prepared starting from 1 total RNA according to Illumina Stranded Total RNA prep Ligation with Ribo-Zero Plus kit (Illumina Inc., San Diego, CA, USA).